Goldman Sachs & Co. LLC, TD Cowen and Wells Fargo Securities acted as joint book-running managers for the offering.

Annexon Biosciences ( ($ANNX) ) has issued an update. On November 12, 2025, Annexon, Inc. announced an underwritten public offering of 25,096,153 ...

Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy ...

PREVAIL phase III trial of gefurulimab meets its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in MG-ADL ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Certainly, cravings can get the best of us and in some cases too much of what we crave can result in some unhealthy outcomes.

Annexon, Inc. ('Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

A tousled medium-length haircut is incredibly versatile. As seen on Kerry Washington here, it works just as well on the red ...

Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and ...